var data={"title":"Dexmedetomidine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dexmedetomidine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6000?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dexmedetomidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dexmedetomidine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=dexmedetomidine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dexmedetomidine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158352\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Precedex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158353\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Precedex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158371\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha<sub>2</sub>-Adrenergic Agonist;</li>\n      <li>\n        Sedative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158356\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Errors have occurred due to misinterpretation of dosing information. Maintenance dose expressed as mcg/kg/<b>hour</b>. Individualized and titrated to desired clinical effect.  At recommended doses, dexmedetomidine does not provide adequate and reliable amnesia (when necessary); therefore, use of additional agents with amnestic properties (eg, benzodiazepines) may be necessary (Ebert 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>ICU sedation:</b> IV: Initial: Loading infusion (optional; see <b>&quot;Note&quot;</b> below) of 1 mcg/kg over 10 minutes, followed by a maintenance infusion (see <b>&quot;Note&quot;</b> below) of 0.2 to 0.7 mcg/kg/<b>hour</b>; adjust rate to desired level of sedation; titration no more frequently than every 30 minutes may reduce the incidence of hypotension (Gerlach 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> <i>Loading infusion:</i> The loading dose may be omitted for this indication if patient is either being converted from another sedative and patient is adequately sedated or there are concerns for hemodynamic compromise. <i>Maintenance infusion:</i> Dosing ranges between 0.2 to 1.5 mcg/kg/<b>hour</b> have been reported during randomized controlled clinical trials (Pandharipande 2007; Riker 2009). Although infusion rates as high as 2.5 mcg/kg/<b>hour</b> have been used, it is thought that doses &gt;1.5 mcg/kg/<b>hour</b> do not add to clinical efficacy (Venn 2003). Manufacturer recommends duration of infusion should not exceed 24 hours; however, randomized clinical trials have demonstrated efficacy and safety comparable to lorazepam and midazolam with longer-term infusions of up to ~5 days (Pandharipande 2007; Riker 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Procedural sedation:</b> IV: Initial: Loading infusion of 1 mcg/kg (or 0.5 mcg/kg for less invasive procedures [eg, ophthalmic]) over 10 minutes, followed by a maintenance infusion of 0.6 mcg/kg/<b>hour</b>, titrate to desired effect; usual range: 0.2 to 1 mcg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Fiberoptic intubation (awake):</i> IV: Initial: Loading infusion of 1 mcg/kg over 10 minutes, followed by a maintenance infusion of 0.7 mcg/kg/<b>hour</b> until endotracheal tube is secured (Bergese 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Craniotomy (awake) (off-label use):</b> IV: Initial: Loading infusion of 0.5 to 1 mcg/kg over 10 to 20 minutes, followed by a maintenance infusion of 0.5 mcg/kg/<b>hour</b>, titrate to desired effect (Bekker 2001; Bekker, 2008; Piccioni 2008; Shen 2013); usual range: 0.1 to 0.7 mcg/kg/<b>hour</b> (Piccioni 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158357\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>ICU sedation:</b> IV: Refer to adult dosing. Consider dosage reduction. No specific guidelines available. Dose selections should be cautious, at the low end of dosage range; titration should be slower, allowing adequate time to evaluate response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Procedural sedation:</b> IV: Refer to adult dosing: Initial: Loading infusion of 0.5 mcg/kg over 10 minutes; Maintenance infusion: Dosage reduction should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158358\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, pharmacokinetics were not significantly different in patients with severe renal impairment (CrCl &lt;30 mL/minute).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158359\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, consider a dose reduction. Clearance is reduced in varying degrees based on the level of impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158336\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mcg/4 mL (4 mL); 1000 mcg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Precedex: 400 mcg/100 mL (100 mL); 200 mcg/2 mL (2 mL) [additive free, latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Precedex: 200 mcg/50 mL (50 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Precedex: 80 mcg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mcg/2 mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158321\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158338\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer using a controlled infusion device. Advisable to use administration components made with synthetic or coated natural rubber gaskets. If loading dose used, administer over 10 minutes; may extend to 20 minutes to further reduce vasoconstrictive effects. Titration no more frequently than every 30 minutes may reduce the incidence of hypotension when used for ICU sedation (Gerlach 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471305\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 200 mcg in 50 mL (concentration: 4 mcg/mL) of NS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471306\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 4 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158337\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intensive care unit sedation:</b> Sedation of initially-intubated and mechanically-ventilated patients during treatment in an intensive care setting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Procedural sedation:</b> Procedural sedation prior to and/or during awake fiberoptic intubation; sedation prior to and/or during surgical or other procedures of nonintubated patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475094\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Sedation during awake craniotomy; Treatment of shivering</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158379\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Precedex may be confused with Peridex</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Errors have occurred due to misinterpretation of dosing information; use caution. Maintenance dose expressed as mcg/kg/<b>hour</b>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158328\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency dependent upon dose, duration, and indication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypotension (24% to 56%), bradycardia (5% to 42%), systolic hypertension (28%), tachycardia (25%), hypertension (diastolic; 12%), hypertension (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Agitation (5% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Constipation (6% to 14%), nausea (3% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Respiratory depression (37%; placebo 32%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Atrial fibrillation (2% to 9%), peripheral edema (3% to 7%), hypovolemia (3%), edema (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Anxiety (5% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypokalemia (9%), hyperglycemia (7%), hypoglycemia (5%), increased thirst (2%), hypocalcemia (1%), hypomagnesemia (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Xerostomia (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Oliguria (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Acute renal failure (2% to 3%), decreased urine output (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Respiratory failure (2% to 10%), adult respiratory distress syndrome (1% to 9%), pleural effusion (2%), wheezing (&le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (5% to 7%), withdrawal syndrome (ICU sedation; 3% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Abdominal pain, acidosis, apnea, atrioventricular block, bronchospasm, cardiac arrhythmia, cardiac disease, chills, confusion, convulsions, decreased visual acuity, delirium, diaphoresis, diarrhea, dizziness, drug tolerance (use &gt;24 hours), dyspnea, extrasystoles, hallucination, headache, heart block, hemorrhage, hepatic insufficiency, hyperbilirubinemia, hypercapnia, hyperkalemia, hypernatremia, hyperpyrexia, hypoventilation, hypoxia, illusion, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, inversion T-wave on ECG, myocardial infarction, neuralgia, neuritis, pain, photopsia, polyuria, prolonged Q-T interval on ECG, pulmonary congestion, respiratory acidosis, rigors, seizure, sinoatrial arrest, speech disturbance, supraventricular tachycardia, tachyphylaxis (use &gt;24 hours), variable blood pressure, ventricular arrhythmia, ventricular tachycardia, visual disturbance, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158341\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the U.S. manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to dexmedetomidine or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158325\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Episodes of bradycardia, hypotension, and sinus arrest have been associated with rapid IV administration (eg, bolus administration) or when given to patients with high vagal tone. When used for ICU sedation, use of a loading dose is optional; for the maintenance infusion, titration no more frequently than every 30 minutes may reduce the incidence of hypotension (Gerlach 2009). If medical intervention is required, treatment may include stopping or decreasing the infusion, increasing the rate of IV fluid administration, use of pressor agents, and elevation of the lower extremities. At low concentrations, mean arterial pressure (MAP) may be reduced without changes in other hemodynamic parameters (eg, pulmonary artery occlusion pressure [PAOP]); however, at higher concentrations (&gt;1.9 ng/mL), MAP, CVP, PAOP, PVR, and SVR increase (Ebert 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transient hypertension: Has been primarily observed during loading dose administration and is associated with the initial peripheral vasoconstrictive effects of dexmedetomidine. Treatment is generally unnecessary; however, reduction of infusion rate may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart block, bradycardia, severe ventricular dysfunction, hypovolemia, or chronic hypertension. In a scientific statement from the American Heart Association, dexmedetomidine has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; cardiovascular adverse events (eg, bradycardia, hypotension) may be more pronounced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reductions recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; cardiovascular events (eg, bradycardia, hypotension) may be more pronounced. Dose reduction may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arousability: Patients may be arousable and alert when stimulated. This alone should not be considered as lack of efficacy in the absence of other clinical signs/symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: Should be administered only by persons skilled in management of patients in intensive care setting or operating room. Patients should be continuously monitored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance and tachyphylaxis: Use of infusions &gt;24 hours has been associated with tolerance and tachyphylaxis and dose-related increase in adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: When withdrawn abruptly in patients who have received &gt;24 hours of therapy, withdrawal symptoms may result (eg, hypertension, tachycardia, nervousness, nausea, vomiting, agitation, headaches). Use for &gt;24 hours is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158366\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158330\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8897&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Inhibitors (Moderate): May decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Inhibitors (Strong): May decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158332\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6826804\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in some animal reproduction studies. Dexmedetomidine is expected to cross the placenta. Information related to use during pregnancy is limited (El-Tahan 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20305962\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dexmedetomidine is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158334\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Level of sedation; heart rate, respiration, rhythm, blood pressure; pain control.<b> Note:</b> Dexmedetomidine causes minimal respiratory depression, inhibits salivation, and is analgesic-sparing. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Critically-ill mechanically ventilated patients: Monitor depth of sedation with either the Richmond Agitation-Sedation Scale (RASS) or Sedation-Agitation Scale (SAS) (Barr 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158324\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective alpha<sub>2</sub>-adrenoceptor agonist with anesthetic and sedative properties thought to be due to activation of G-proteins by alpha<sub>2a</sub>-adrenoceptors in the brainstem resulting in inhibition of norepinephrine release; peripheral alpha<sub>2b</sub>-adrenoceptors are activated at high doses or with rapid IV administration resulting in vasoconstriction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158340\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV loading dose: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: 45 to 60 minutes (Yuen 2007), may be faster in pediatric patients when administered via an atomizing device (Talon 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peak effect:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV loading dose: 15 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: 90 to 105 minutes (Yuen 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration (dose dependent): 60 to 120 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm Neonates (28 to &lt;36 weeks GA): 2.7 L/kg (range: 2.5 to 5.9 L/kg) (Chrysostomou 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term neonates (36 to &le;44 weeks GA): 3.9 L/kg (range: 0.1 to 10.9 L/kg) (Chrysostomou 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;2 years: Median: 3.8 L/kg (range: 1.9 to 4.6 L/kg) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 11 years: Median: 2.2 L/kg (range: 1.3 to 2.8 L/kg) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~118 L; rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Intranasal: Variable: Median: 65% (range: 35% to 93%) (Iirola 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~94%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via N-glucuronidation, N-methylation, and CYP2A6</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm Neonates (28 to &lt;36 weeks GA): Terminal: 7.6 hours (range: 3 to 9.1 hours) (Chrysostomou 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Term Neonates (36 to &le;44 weeks GA): Terminal: Median: 3.2 hours (range: 1 to 9.4 hours) (Chrysostomou 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;2 years: Terminal: Median: 2.3 hours (range: 1.5 to 3.3 hours) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 11 years: Terminal: Median: 1.6 hours (range: 1.2 to 2.3 hours) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Distribution: ~6 minutes; Terminal: ~up to 3 hours (Venn 2002); significantly prolonged in patients with severe hepatic impairment (Cunningham 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Intranasal: Median: 38 minutes (range: 15 to 60 minutes) (Iirola 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (95%); feces (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Clearance following cardiac surgery was reduced by 27% in pediatric patients aged 1 week to 14 years (Potts 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preterm Neonates (28 to &lt;36 weeks GA): 0.3 L/hour/kg (0.2 to 0.4 L/hour/kg) (Chrysostomou 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Term Neonates (36 to &le;44 weeks GA): 0.9 L/hour/kg (0.2 to 1.5 L/hour/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;2 years: Median: 1 L/hour/kg (0.85 to 1.66 L/hour/kg) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 11 years: Median: 1 L/hour/kg (0.56 to 1.35 L/hour/kg) (Vilo 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: ~39 L/hour; Hepatic impairment (Child-Pugh class A, B, or C): Mean clearance values were 74%, 64%, and 53% respectively, of those observed in healthy adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323099\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dexmedetomidine HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/2 mL (2 mL): $22.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400MCG/4ML (4 mL): $94.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000MCG/10ML (10 mL): $233.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Precedex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mcg/20 mL (20 mL): $31.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/2 mL (2 mL): $50.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/50 mL (50 mL): $55.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg/100 mL (100 mL): $100.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F158343\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cepedex (AT);</li>\n      <li>Demesynt (CR, DO, GT, HN, PA, SV);</li>\n      <li>Demsynt (NI);</li>\n      <li>Detomax IV (BD);</li>\n      <li>Dexdomitor (AT);</li>\n      <li>Dexdor (AT, DK, ES, HR, HU, IE, LT, LV, MT, NL, PL, RO, TR, UA);</li>\n      <li>Dexem (LK);</li>\n      <li>Meproxidina (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Precedex (AE, AR, AU, BH, BR, CR, CZ, DO, GT, HK, HN, ID, JO, KR, KW, LB, MX, MY, NI, NZ, PA, PE, PH, QA, SA, SG, SV, TH, TW, UY, VN);</li>\n      <li>Sedadex (AT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aho MS, Erkola OA, Scheinin H, et al, &ldquo;Effect of Intravenously Administered Dexmedetomidine on Pain After Laparoscopic Tubal Ligation,&rdquo; <i>Anesth Analg</i>, 1991, 73(2):112-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/1854025/pubmed\" target=\"_blank\" id=\"1854025\">1854025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arain SR and Ebert TJ, &ldquo;The Efficacy, Side Effects, and Recovery Characteristics of Dexmedetomidine Versus Propofol When Used for Intraoperative Sedation,&rdquo; <i>Anesth Analg</i>, 2002, 95(2):461-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/12145072/pubmed\" target=\"_blank\" id=\"12145072\">12145072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddigam K, Russo P, Russo J, et al, &ldquo;Dexmedetomidine in the Treatment of Withdrawal Syndromes in Cardiothoracic Surgery Patients,&rdquo; <i>J Intensive Care Med</i>, 2005, 20(2):118-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/15855224/pubmed\" target=\"_blank\" id=\"15855224\">15855224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bekker AY, Kaufman B, Samir H, Doyle W. The use of dexmedetomidine infusionfor awake craniotomy. <i>Anesth Analg</i>. 2001;92(5):1251-1253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/11323355/pubmed\" target=\"_blank\" id=\"11323355\">11323355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bekker A, Sturaitis M, Bloom M, et al, &ldquo;The Effect of Dexmedetomidine on Perioperative Hemodynamics in Patients Undergoing Craniotomy,&rdquo; <i>Anesth Analg</i>, 2008, 107(4):1340-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/18806050/pubmed\" target=\"_blank\" id=\"18806050\">18806050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belleville JP, Ward DS, Bloor BC, et al, &ldquo;Effects of Intravenous Dexmedetomidine in Humans I. Sedation, Ventilation, and Metabolic Rate,&rdquo; <i>Anesthesiology</i>, 1992, 77(6):1125-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/1361310/pubmed\" target=\"_blank\" id=\"1361310\">1361310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergese SD, Candiotti KA, Bokesch PM, et al, &ldquo;A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine for Sedation During Awake Fiberoptic Intubation,&rdquo; <i>Am J Ther</i>, 2010, 17(6):586-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/20535016/pubmed\" target=\"_blank\" id=\"20535016\">20535016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berkenbosch JW, Wankum PC, and Tobias JD, &ldquo;Prospective Evaluation of Dexmedetomidine for Noninvasive Procedural Sedation in Children,&rdquo; <i>Pediatr Crit Care Med</i>, 2005, 6(4):435-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/15982430/pubmed\" target=\"_blank\" id=\"15982430\">15982430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chrysostomou C, Schulman SR, Herrera Castellanos M, et al. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. <i>J Pediatr</i>. 2014;164(2):276-282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/24238862/pubmed\" target=\"_blank\" id=\"24238862\">24238862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunningham FE, Baughman VL, Tonkovich L, et al. Pharmacokinetics of dexmedetomidine (DEX) in patients with hepatic failure (HF). <i>Clin Pharmacol Ther.</i> 1999;65:128.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dexmedetomidine Injection [prescribing information]. Paramus, NJ; WG Critical Care LLC: September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ebert TJ, Hall JE, Barney JA, et al. The effects of increasing plasma concentrations of demedetomidine in humans. <i>Anesthesiology</i>. 2000;93:382-394.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/10910487/pubmed\" target=\"_blank\" id=\"10910487\">10910487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    El-Tahan MR, Mowafi HA, Al Sheikh IH, et al, &quot;Efficacy of Dexmedetomidine in Suppressing Cardiovascular and Hormonal Responses to General Anaesthesia for Caesarean Delivery: A Dose-Response Study,&quot; <i>Int J Obstet Anesth</i>, 2012, 21(3):222-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/22681971/pubmed\" target=\"_blank\" id=\"22681971\">22681971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerlach AT and Dasta JF, &ldquo;Dexmedetomidine: An Updated Review,&rdquo; <i>Ann Pharmacother</i>, 2007, 41(2):245-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/17299013/pubmed\" target=\"_blank\" id=\"17299013\">17299013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerlach AT, Dasta JF, Steinberg S, et al, &ldquo;A New Dosing Protocol Reduces Dexmedetomidine-Associated Hypotension in Critically Ill Surgical Patients,&rdquo; <i>J Crit Care</i>, 2009, 24(4):568-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/19682844/pubmed\" target=\"_blank\" id=\"19682844\">19682844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenhalgh DL and Kumar CM, &ldquo;Sedation During Ophthalmic Surgery,&rdquo; <i>Eur J Anaesthesiol</i>, 2008, 25(9):701-7<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/18471335/pubmed\" target=\"_blank\" id=\"18471335\">18471335</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ickeringill M, Shehabi Y, Adamson H, et al, &ldquo;Dexmedetomidine Infusion Without Loading Dose in Surgical Patients Requiring Mechanical Ventilation: Haemodynamic Effects and Efficacy,&rdquo; <i>Anaesth Intensive Care</i>, 2004, 32(6):741-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/15648981/pubmed\" target=\"_blank\" id=\"15648981\">15648981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iirola T, Vilo S, Manner T, et al. Bioavailability of dexmedetomidine after intranasal administration. <i>Eur J Clin Pharmacol</i>. 2011;67(8):825-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/21318594/pubmed\" target=\"_blank\" id=\"21318594\">21318594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lev&auml;nen J, M&auml;kel&auml; ML, and Scheinin H, &ldquo;Dexmedetomidine Premedication Attenuates Ketamine-induced Cardiostimulatory Effects and Postanesthetic Delirium,&rdquo; <i>Anesthesiology</i>, 1995, 82(5):1117-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/7741286/pubmed\" target=\"_blank\" id=\"7741286\">7741286</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMorrow SP and Abram TJ, &ldquo;Dexmedetomidine Sedation,&rdquo; <i>Pediatr Emer Care</i>, 2012, 28(3):292-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/22391930 /pubmed\" target=\"_blank\" id=\"22391930 \">22391930 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pandharipande PP, Pun BT, Herr DL, et al, &ldquo;Effect of Sedation With Dexmedetomidine vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated Patients. The MENDS Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2007, 298(22):2644-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/18073360/pubmed\" target=\"_blank\" id=\"18073360\">18073360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phan H and Nahata MC, &ldquo;Clinical Uses of Dexmedetomidine in Pediatric Patients,&rdquo; <i>Paediatr Drugs</i>, 2008, 10(1):49-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/18162008/pubmed\" target=\"_blank\" id=\"18162008\">18162008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Piccioni F and Fanzio M, &ldquo;Management of Anesthesia in Awake Craniotomy,&rdquo; <i>Minerva Anestesiol</i>, 2008, 74(7-8):393-408.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/1861226/pubmed\" target=\"_blank\" id=\"1861226\">1861226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polderman KH and Herold I, &ldquo;Therapeutic Hypothermia and Controlled Normothermia in the Intensive Care Unit: Practical Considerations, Side Effects, and Cooling Methods,&rdquo; <i>Crit Care Med</i>, 2009, 37(3):1101-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/19237924/pubmed\" target=\"_blank\" id=\"19237924\">19237924</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Potts AL, Anderson BJ, Warman GR, Lerman J, Diaz SM, Vilo S. Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. <i>Paediatr Anaesth</i>. 2009;19(11):1119-1129.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/19708909/pubmed\" target=\"_blank\" id=\"19708909\">19708909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Precedex (dexmedetomidine) [prescribing information]. Lake Forest, IL: Hospira Inc; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Precedex (dexmedetomidine) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; March 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riker RR, Shehabi Y, Bokesch PM, et al, &ldquo;Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients. A Randomized Trial,&rdquo; <i>JAMA</i>, 2009, 301(5):489-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/19188334/pubmed\" target=\"_blank\" id=\"19188334\">19188334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehabi Y, Ruettimann U, Adamson H, et al, &ldquo;Dexmedetomidine Infusion for More Than 24 Hours in Critically Ill Patients: Sedative and Cardiovascular Effects,&rdquo; <i>Intensive Care Med</i>, 2004, 30(12):2188-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/15338124/pubmed\" target=\"_blank\" id=\"15338124\">15338124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shen SL, Zheng JY, Zhang J, et al. Comparison of dexmedetomidine and propofol for conscious sedation in awake craniotomy: a prospective, double-blind, randomized, and controlled clinical trial. <i>Ann</i><i>Pharmacother</i>. 2013;47(11):1391-1399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/15338124/pubmed\" target=\"_blank\" id=\"15338124\">15338124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talke P, Tayefeh F, Sessler DI, et al, &ldquo;Dexmedetomidine Does Not Alter the Sweating Threshold, But Comparably and Linearly Decreases the Vasoconstriction and Shivering Thresholds,&rdquo; <i>Anesthesiology</i>, 1997, 87(4):835-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/9357885/pubmed\" target=\"_blank\" id=\"9357885\">9357885</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talon MD, Woodson LC, Sherwood ER, Aarsland A, McRae L, Benham T. Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. <i>J Burn Care Res</i>. 2009;30(4):599-605.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/19506498/pubmed\" target=\"_blank\" id=\"19506498\">19506498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperativepatients requiring intensive care. <i>Br J Anaesth</i>. 2002;88(5):669-675.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/12067004/pubmed\" target=\"_blank\" id=\"12067004\">12067004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venn M, Newman J, and Grounds M, &ldquo;A Phase II Study To Evaluate the Efficacy of Dexmedetomidine for Sedation in the Medical Intensive Care Unit,&rdquo; <i>Intensive Care Med</i>, 2003, 29(2):201-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/12594584/pubmed\" target=\"_blank\" id=\"12594584\">12594584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vilo S, Rautiainen P, Kaisti K, et al. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. <i>Br J Anaesth</i>. 2008;100(5):697-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/18378546/pubmed\" target=\"_blank\" id=\"18378546\">18378546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. <i>Anesth Analg</i>. 2007;105(2):374-380.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dexmedetomidine-drug-information/abstract-text/17646493/pubmed\" target=\"_blank\" id=\"17646493\">17646493</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8897 Version 188.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F158352\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F158353\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F158371\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F158356\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F158357\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F158358\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F158359\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F158336\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F158321\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F158338\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14471305\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471306\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F158337\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475094\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F158379\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F158328\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F158341\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F158325\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F158366\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F158330\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F158332\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6826804\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20305962\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F158334\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F158324\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F158340\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323099\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F158343\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8897|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dexmedetomidine-patient-drug-information\" class=\"drug drug_patient\">Dexmedetomidine: Patient drug information</a></li><li><a href=\"topic.htm?path=dexmedetomidine-pediatric-drug-information\" class=\"drug drug_pediatric\">Dexmedetomidine: Pediatric drug information</a></li></ul></div></div>","javascript":null}